
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
TriSalus Life Sciences Inc. (TLSI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TLSI (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $11.31
1 Year Target Price $11.31
6 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.6% | Avg. Invested days 64 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 147.35M USD | Price to earnings Ratio - | 1Y Target Price 11.31 |
Price to earnings Ratio - | 1Y Target Price 11.31 | ||
Volume (30-day avg) 8 | Beta 0.48 | 52 Weeks Range 3.42 - 5.99 | Updated Date 08/15/2025 |
52 Weeks Range 3.42 - 5.99 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -86.61% | Operating Margin (TTM) -65.39% |
Management Effectiveness
Return on Assets (TTM) -52.51% | Return on Equity (TTM) -496.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 154518162 | Price to Sales(TTM) 4.09 |
Enterprise Value 154518162 | Price to Sales(TTM) 4.09 | ||
Enterprise Value to Revenue 4.29 | Enterprise Value to EBITDA -5.96 | Shares Outstanding 37975800 | Shares Floating 36185692 |
Shares Outstanding 37975800 | Shares Floating 36185692 | ||
Percent Insiders 40.56 | Percent Institutions 9.02 |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences Inc. is a commercial-stage oncology company dedicated to developing and commercializing novel delivery systems designed to improve patient outcomes. The company focuses on addressing limitations in current cancer treatment methods by enhancing drug delivery directly to tumors.
Core Business Areas
- TriNav Infusion System: The TriNav Infusion System is a proprietary, pressure-enabled drug delivery system designed to administer therapeutic agents directly into a tumor's blood supply.
- OncoPreTherapy: OncoPreTherapy is a platform that focuses on priming the tumor microenvironment to enhance the effectiveness of subsequent therapies.
Leadership and Structure
The leadership team includes Mary Szela (CEO), and other key executives. The company operates with a structure focused on research and development, clinical trials, commercialization, and manufacturing.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: The TriNav Infusion System delivers targeted therapy directly to liver tumors. Market share data is not explicitly public. The competitors include companies that offer drug-eluting beads and other intra-arterial therapies for liver cancer like Boston Scientific (BTX) and Merit Medical Systems (MMSI).
- MATCH-BT (Bronchial Tree) Kit: A microcatheter and guidewire for targeted delivery of therapeutics to treat lung cancer with advanced interventional techniques. Market share data is not publicly available. Competitors also include Boston Scientific (BTX) and Merit Medical Systems (MMSI).
Market Dynamics
Industry Overview
The oncology drug delivery market is experiencing growth driven by the increasing prevalence of cancer, advancements in targeted therapies, and the need for more effective treatment options with reduced side effects.
Positioning
TriSalus Life Sciences Inc. is positioned as an innovator in targeted drug delivery for cancer treatment. Their pressure-enabled drug delivery system aims to overcome limitations of traditional methods and improve therapeutic outcomes.
Total Addressable Market (TAM)
The TAM for targeted drug delivery in oncology is estimated to be billions of dollars. TriSalus is positioned to capture a portion of this market by addressing unmet needs in liver and lung cancer treatment.
Upturn SWOT Analysis
Strengths
- Proprietary pressure-enabled drug delivery technology
- Focus on unmet needs in cancer treatment
- Experienced leadership team
- Potential for improved therapeutic outcomes
Weaknesses
- Limited commercial history
- Dependence on key products
- Requires significant investment in R&D and clinical trials
- Highly competitive market
Opportunities
- Expansion into new cancer indications
- Partnerships with pharmaceutical companies
- Increased adoption of targeted therapies
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
- Technological obsolescence
Competitors and Market Share
Key Competitors
- BTX
- MMSI
- Varian Medical Systems (VAR)
- Siemens Healthineers (SEMHF)
Competitive Landscape
TriSalus Life Sciences Inc. possesses innovative targeted drug delivery technology giving it an edge. However it also faces competition from larger well-established medical device companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its status as a relatively new public company and clinical stage company.
Future Projections: Future growth projections are based on the success of clinical trials, regulatory approvals, and commercial adoption of TriNav and MATCH BT kit. Analyst estimates are not readily available due to limited coverage.
Recent Initiatives: Recent initiatives include advancing clinical trials for TriNav and MATCH BT kit, expanding partnerships, and scaling up manufacturing capabilities.
Summary
TriSalus Life Sciences is a newly public, clinical-stage oncology company with innovative drug delivery technology, particularly its TriNav Infusion System and MATCH BT kit. This technology holds promise for improving cancer treatment outcomes. However, the company faces risks related to regulatory approvals, market adoption, and competition from larger, well-established medical device companies. The long-term success of TriSalus depends on positive clinical trial results and successful commercialization efforts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Market Research Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimates and may not be precise. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-10 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com |
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.